FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
	09/491,500	January 26, 2000
APPLICANT		GROUP
Keith L. Black and Nagendra S. Ningaraj		1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AMJ	AA	5,518,499	05/21/06	Agar			
AMJ	AB	5,767,160	06/16/98	Kaesemeyer			

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AMJ	AC		Armstead, W.M., *Contribution of kca channel activation to hypoxic cerebrovasodilation does not involve NO*, Brain Res, 799:44-48 (1998). ABSTRACT ONLY.
	AD		Barna, M., et al., *Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection*, Virology, 223: 331-343 (1996).
	AE		Becker, E.M., et al., *The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rate platelets*, J Cardiovasc Pharmacol, 35(3):390-7 (2000). ABSTRACT ONLY.
	AF		Boje, K.M., *Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis*, Brain Research, 720:75-83 (1996).
	AG		Brandt, L., et al., *Effects of topical application of calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia*, Journal of Cerebral Blood Flow and Metabolism, 3:44-50 (1983).
	AH		Brioni, J.D., et al., *Activators of soluble guanylate cyclase for treatment of male erectile dysfunction*, International Journal of Impotence Research, 14:8-14 (2002).
	AI		Bychkov, R., et al. *Calicum-activated potassium channels and nitrate-induced vasodilation in human coronary arteries, J Pharacol Exp Therap, 285:293-8 (1998). ABSTRACT ONLY.*
	AJ		Chandran, S., et al., *Nitric oxide: concepts, current perspectives and future therapeutic implications*, Indian Journal of Pharmacology, 30:351-366 (1998).
	AK		Chi, O.Z., et al. *Effect of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia, Pharmacologylogy, 48:367-373 (1994).*
	AL		Cloughesy, T.F., et al., *Pharmacological blood-brain barrier modification for selective drug delivery*, Journal of Neuro-Oncology, 26:125-132 (1995).
	AM		Feelisch, M., *The use of nitric oxide donors in pharmacological studies*, Naunyn-Schmiedeberg's Arch Pharmcol, 358:113-122 (1998).
	AN		Fukao, M., et al., *Cyclic GMP-dependent protein kindase activates cloned BKCa channels expressed in mammalian cells by direct phophorylation at serine 1072*, J Biol Chem, 274(16):10927-35 (1999).
	AO		Fukumura, D., et al., *Role of nitric oxide in angiogenesis and microcirculation in tumors*, Cancer and Metastasis Reviews, 17:77-89 (1998).
↓	AP		He, P., et al., *cGMP modulates basal and activated microvessel permeability independenty of [Ca2+]i*, Am J Physiol, 274:H1865-74 (1998). ABSTRACT ONLY.
AMJ	AQ		Herrera, G.M., et al., *Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis*, J Cardiovasc Pharmacol, 31:921-9 (1998). ABSTRACT ONLY

EXAMINER	DATE CONSIDERED
Anne-Marie Falk	8/30/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO. 09/491,500	FILING DATE January 26, 2000
APPLICANT Keith L. Black and Nagendra S. Ningaraj		GROUP 1632

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

Amz	AR		Holschermann, H., et al., *Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells*, Am J Physiol, 272:H91-8 (1997). ABSTRACT ONLY.
	AS		Hongli, X., et al., *Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma*, Chinese Medical Journal, 111(8):751-753 (1998).
	AT		Hurst, R.D., et al., *Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier*, Journal of Cellular Physiology, 167:89-94 (1996).
	AU		Inamura, T., et al., *Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma*, Neurological Research, 16:125-128 (1994).
	AV		Inamura, T., et al., *Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors*, J Neurosurg, 81:752-758 (1994).
	AW		Janigro, D., et al., *Regulation of blood-brain barrier endothelial cells by nitric oxide*, Circulation Research, 75:528-528 (1994).
	AX		Kimura, M., et al., *Responses of human basilar and other isolated arteries to novel nitric oxide donors*, J Cardiovasc Pharmacol, 32: 695-701 (1998). ABSTRACT ONLY.
	AY		Koesling, D., *Modulators of soluble guanylyl cyclase*, Naunyn-Schmiedeberg's Arch Pharmacol, 358:123-126 (1998).
	AZ		Liu, Y., et al., *Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma*, Neurological Research, 23:631-639 (2001).
	BA		Lohse, M.J., et al., *Pharmacology of NO:cGMP signal transduction*, Naunyn-Schmiedeberg's Arch Pharmcol, 358:111-112 (1998).
	BB		Matukado, T., et al., *Selective Increase in Blood Tumor Permeability by Calcium Antagonists in Transplanted* Brain Tumors, Acta Neurochir, 60: 403-405 (1994).
	BC		Mayer, B., et al., *Nitric oxide synthases: catalytic function and progress toward selective inhibition*, Naunyn-Schmiedeberg's Arch Pharmcol, 358:127-133 (1998).
	BD		Mayhan, W.G., *Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier*, Brain Research, 743:70-76 (1996).
	BE		Mayhan, W.G., et al., *Glutamate-induced disruption of the blood-brain barrier in rats*, Stroke, *27:965-970 (1996).*
	BF		Nakano, S., et al., *Increased brain microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide*, Cancer Research, 56:4027-4031 (1996).
Amz	BG		Ningaraj, N.S., et al., *Role of ATP-sensitive K+ channels in blood-brain tumor barrier permeability*, Congress of Neurological Surgeons Annual Meeting, 50th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No. 4309, p. 215.

EXAMINER Anne-Marie Falk	DATE CONSIDERED 8/30/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
	09/491,500	January 26, 2000
APPLICANT: Keith L. Black and Nagendra S. Ningaraj		GROUP: 1632

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AM2	BH		Ningaraj, N.S., et al., Ca2+ -dependent K+ channels are a key regulatory of blood-brain tumor barrier permeability, Congress of Neurological Surgeons Annual Meeting, 50th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No.428, p. 219.
	BI		Ningaraj, N.S., et al., *Nitric oxide donors increase blood-brain tumor barrier permeability via Kca channels,* Society for Neuroscience, 30th Annual Meeting, New Orleans, LA, November 4-9, 2000, 26 Part 1, p. 338, ABSTRACT No. 126.8.
	BJ		Ningaraj, N.S., et al., Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels, The Journal of Pharmacology, June 2002, 301: 838-851
	BK		Pardrige, W., et al., *Blood -brain barrier and new approaches to drug delivery,* West J Med, 156:281-286 (1992).
	BL		Robertson, B.E., et al., *cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells,* Am J Physiol, 265:C299-C303 (1993).
	BM		Sobey, C.G., et al., *Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide,* Br J Pharmacol, 126:1437-43 (1999). ABSTRACT ONLY.
	BN		Salom, J.B., et al., *Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery,* Pharmacology, 57:79-97 (1998). ABSTRACT ONLY.
	BO		Salom, J.B., et al., *Comparative relaxant effects of the NO donors sodium nitroprusside, DEA/NO and SPER/NO in rabbit carotid arteries,* Gen Pharmacol, 32:75-59 (1999). ABSTRACT ONLY.
	BP		Salom, J.B., et al., *Relexant effects of sodium nitroprusside and NONates in goat middle cerebral artery: delayed impairment of global ischemia-reperfusion,* Nitric Oxide, 3:85-93 (1999). ABSTRACT ONLY.
	BQ		Shukla, A., et al., *Nitric oxide-dependent blood-brain barrier permeability alteration in the rat brain,* Experientia, 52:136-140 (1996).
	BR		Smolenski, A., et al., *Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects,* Naunyn-Schmiedeberg's Arch Pharmacol, 358:134-138.
V	BS		Sugita, M., et al., *Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability in brain tumors,* Cancer Research, 58:914-920 (1998).
	BT		Takayasu, M., et al., *Effects of calcium antagonists on intracerebral penetrating arteriolesi in rats,* J Neurosurg, 69:104-109 (1988).
AM2	BU		Uchida, M., et al., Overexpression of bradykinin type 2 receptors on glioma cells enhances bradykinin-mediated blood-brain tumor varrier permeability increase, Neurological Research, 24:739-745

EXAMINER: Anne-Marie Falk — DATE CONSIDERED: 8/30/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
	09/491,500	January 26, 2000
APPLICANT		**GROUP**
Keith L. Black and Nagendra S. Ningaraj		1632

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

Amz	BV		Uchida, M., et al., *Cyclic GMP-dependent blood-brain tumor barrier permeability is not mediated by cyclic GMP-dependent protein kinase*, Congress of Neurological Surgeons Annual Meeting, 50th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention center, San Antonio, Texas, ABSTRACT No. 440, p. 220.
	BW		Vodovotz, Y., et al., *Regulation of transforming growth factor beta 1 by nitric* oxide, Cancer Res, 59:2142-9 (1999). ABSTRACT ONLY.
	BX		Yukabu, M.A., *Hematoma-induced enhanced cerebral vasoconstriction to leukotriene C4 and endothelin-1 piglets: role of prostanoids*, Pediatr Res, 38:119-23 (1995). ABSTRACT ONLY.
	BY		Tocris Web Page, http://www.tocris.com/cat/nodonorstxt.html No Donors/Precursors, pp.1-2, Downloaded 5/31/00.
Amz	BZ		Sigma-Aldrich Web page, http://vsearch.sial.com/search 97cgi/s97-cgi, p.1, downloaded 5/31/00.

EXAMINER Ame-Marie Falke DATE CONSIDERED 8/30/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.